Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E–mutant metastatic colorectal cancer: Safety lead-in results from the phase III BEACON Colorectal Cancer Study

Eric Van Cutsem, Sanne Huijberts, Axel Grothey, Rona Yaeger, Pieter Jan Cuyle, Elena Elez, Marwan Fakih, Clara Montagut, Marc Peeters, Takayuki Yoshino, Harpreet Wasan, Jayesh Desai, Fortunato Ciardiello, Ashwin Gollerkeri, Janna Christy-Bittel, Kati Maharry, Victor Sandor, Jan H.M. Schellens, Scott Kopetz, Josep Tabernero

Research output: Contribution to journal › Article › peer-review

88 Scopus citations

Fingerprint

Dive into the research topics of 'Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E–mutant metastatic colorectal cancer: Safety lead-in results from the phase III BEACON Colorectal Cancer Study'. Together they form a unique fingerprint.

Medicine & Life Sciences